Was the RVMD insider sale by Mancini a discretionary trade or tax-related?

The sale was tax-related. A footnote explains the 4,615 shares were sold under an automatic sell-to-cover arrangement following restricted stock unit vesting, solely to satisfy applicable withholding taxes, distinguishing it from a voluntary, discretionary sale in the open market.

Revolution Medicines (RVMD) executive executes automatic tax sale after RSU vesting

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Revolution Medicines executive Anthony Mancini reported an automatic sale of shares to cover taxes on vested stock units. On the transaction date, 4,615 shares of common stock were sold in open-market trades at a weighted average price of $156.1192 per share.

The filing explains that this was an automatic sell-to-cover solely for applicable withholding taxes following restricted stock unit vesting, rather than a discretionary sale. After the transaction, Mancini held 49,975 shares directly, including 43,700 restricted stock units and 190 shares acquired under the company’s Employee Stock Purchase Plan.

Insights

Small automatic tax sale after RSU vesting; position remains sizable.

The filing shows Anthony Mancini sold 4,615 Revolution Medicines shares at a weighted average of $156.1192. A footnote states this was an automatic sell-to-cover following restricted stock unit vesting, used solely to pay withholding taxes.

This pattern is typical of equity compensation and carries weak informational value compared with a discretionary sale. After the sale, Mancini still holds 49,975 shares, including 43,700 restricted stock units and 190 shares from the Employee Stock Purchase Plan, indicating the transaction affects only a small portion of his overall equity exposure.

Insider Trade Summary

Net Seller: 4,615 shares ($720,490)

Net Sell 1 txn

Insider Mancini Anthony

Role See Remarks

Sold 4,615 shs ($720K)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,615	$156.1192	$720K

Holdings After Transaction: Common Stock — 49,975 shares (Direct, null)

Footnotes (1)

Pursuant to an automatic sell-to-cover, the shares were sold following the vesting of the restricted stock units solely to cover applicable withholding taxes. This transaction was executed in multiple trades at prices ranging from $156.1105 to $156.8250. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Includes 43,700 Restricted Stock Units. Includes 190 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2026.

Key Figures

Shares sold: 4,615 shares Weighted average sale price: $156.1192 per share Shares held after transaction: 49,975 shares +2 more

5 metrics

Shares sold 4,615 shares Automatic sell-to-cover on 2026-06-16

Weighted average sale price $156.1192 per share Open-market sale to cover taxes

Shares held after transaction 49,975 shares Direct ownership following sale

Restricted stock units included 43,700 RSUs Part of post-transaction holdings

ESPP shares included 190 shares Acquired under Employee Stock Purchase Plan on May 31, 2026

Key Terms

automatic sell-to-cover, restricted stock units, Employee Stock Purchase Plan

3 terms

automatic sell-to-cover financial

"Pursuant to an automatic sell-to-cover, the shares were sold following the vesting of the restricted stock units solely to cover applicable withholding taxes."

restricted stock units financial

"Pursuant to an automatic sell-to-cover, the shares were sold following the vesting of the restricted stock units solely to cover applicable withholding taxes."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Employee Stock Purchase Plan financial

"Includes 190 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2026."

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/18/2026 - 04:11 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mancini Anthony

(Last)

(First)

(Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY

CALIFORNIA

94063

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/16/2026		S⁽¹⁾		4,615	D	$156.1192⁽²⁾	49,975⁽³⁾⁽⁴⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Pursuant to an automatic sell-to-cover, the shares were sold following the vesting of the restricted stock units solely to cover applicable withholding taxes.

2. This transaction was executed in multiple trades at prices ranging from $156.1105 to $156.8250. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. Includes 43,700 Restricted Stock Units.

4. Includes 190 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2026.

Remarks:

Chief Global Commercialization Officer

	/s/ Jack Anders, as Attorney-in-fact for Anthony Mancini	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Anthony Mancini do in this Revolution Medicines (RVMD) Form 4 filing?

Anthony Mancini reported an automatic sale of 4,615 Revolution Medicines common shares. The shares were sold in open-market transactions to cover withholding taxes triggered by the vesting of restricted stock units, rather than as a discretionary portfolio decision.

How many Revolution Medicines shares did Mancini sell and at what price?

Mancini sold 4,615 shares of Revolution Medicines common stock at a weighted average price of $156.1192 per share. A footnote notes the sale occurred in multiple trades between $156.1105 and $156.8250, all executed as part of the same tax-related transaction.

How many Revolution Medicines shares does Mancini hold after this Form 4 transaction?

After the transaction, Mancini directly holds 49,975 Revolution Medicines shares. This total includes 43,700 restricted stock units and 190 shares previously acquired under the company’s Employee Stock Purchase Plan, showing he retains a substantial ongoing equity interest.

What do the restricted stock units in Mancini’s RVMD holdings represent?

The filing notes that Mancini’s post-transaction holdings include 43,700 restricted stock units. These RSUs represent a right to receive Revolution Medicines shares upon vesting, providing additional equity exposure beyond his already-issued common stock position reported in the Form 4.

What does the Employee Stock Purchase Plan detail in the RVMD Form 4 footnotes?

One footnote states that Mancini’s holdings include 190 shares acquired under Revolution Medicines’ Employee Stock Purchase Plan on May 31, 2026. This plan allows eligible employees to buy company shares, typically through payroll deductions, as part of their overall compensation package.